The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2014Prevention of Levodopa-induced Dyskinesia by Transcranial Static Magnetic Field Stimulation
Study Rationale:
A major challenge in Parkinson’s treatment is the management of levodopa-induced dyskinesias. A promising approach is offered by non-invasive neuromodulation techniques. We recently... -
Research Grant, 2014Predicting the Efficacious Dose of the Selective 5-HT1A Agonist NLX-112
Study Rationale:
The dopamine precursor levodopa is the gold-standard treatment for Parkinson’s disease. However, as PD progresses, serotonin neurons increasingly convert levodopa to... -
Rapid Response Innovation Awards, 2014Identifying and Characterizing Genetic Causes of REM Sleep Behavior Disorder and Parkinson’s Disease
Study Rationale:
During the rapid eye movement (REM) phase of sleep, when we dream, our voluntary muscles are paralyzed so that we would not act out our dreams. In REM sleep behavior... -
Dyskinesia Challenge, 2014Gene-to-gene Interaction Analysis of Levodopa-induced Dyskinesia
Study Rationale:
Long-term treatment for Parkinson’s with levodopa can cause dyskinesia or involuntary movements. Other drugs like anti-dopaminergics can cause similar abnormal... -
Research Grant, 2014Neuromelanin in Circulating Phagocytes May Reveal Early Neurodegeneration in Parkinson's Disease Supplement
Promising Outcomes of Original Grant:
The pigment neuromelanin is specifically found in the nerves destroyed by Parkinson’s disease. We developed a way to measure neuromelanin and then looked for... -
Research Grant, 2014Phase IB Follow-up Study to Assess Boost Immunization with AFFITOPE® PD01A
Study Rationale:
PD01A is an alpha-synuclein-targeting vaccine. Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease, and its reduction is expected...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.